Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2023 May 31;9(9):598-601.
doi: 10.1016/j.hrcr.2023.05.014. eCollection 2023 Sep.

Delayed embolization of next-generation left atrial appendage closure device in an asymptomatic patient

Affiliations
Case Reports

Delayed embolization of next-generation left atrial appendage closure device in an asymptomatic patient

Aditi Bhagat et al. HeartRhythm Case Rep. .
No abstract available

Keywords: Atrial fibrillation; Embolization; Left atrial appendage occlusion; Transesophageal echocardiography.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Immediate preimplantation transesophageal echocardiography views of left atrial appendage (LAA). A: View illustrates the width of the LAA at 0 degrees. B: View illustrates the length and width of the LAA at 40 degrees. C: View illustrates the length and width of the LAA at 90 degrees. D: View illustrates the length and width of the LAA at 135 degrees.
Figure 2
Figure 2
Immediate postimplantation views of the Watchman FLX version 2 device (Boston Scientific). A: Immediately postimplantation of Watchman device shows no peri-device leak at 45 degrees. B: View illustrates the width of the left atrial appendage (LAA) at 0 degrees. C: View illustrates the length and width of the LAA at 40 degrees. D: View illustrates the length and width of the LAA at 90 degrees. D: View illustrates the length and width of the LAA at 135 degrees.
Figure 3
Figure 3
Follow-up transesophageal echocardiogram 35 days after the Watchman FLX version 2 device (Boston Scientific) is implanted. Images illustrate the device position at the left ventricular outflow tract and mitral valve.

Similar articles

Cited by

References

    1. Reddy V.Y., Doshi S.K., Kar S., et al. 5-Year outcomes after left atrial appendage closure: from the PREVAIL and PROTECT AF trials. J Am Coll Cardiol. 2017;70:2964–2975. - PubMed
    1. Belgaid D.R., Khan Z., Zaidi M., Hobbs A. Prospective randomized evaluation of the watchman left atrial appendage closure device in patients with atrial fibrillation versus long-term warfarin therapy: The PREVAIL trial. Int J Cardiol. 2016;219:177–179. - PubMed
    1. Fountain R.B., Holmes D.R., Chandrasekaran K., et al. The PROTECT AF (WATCHMAN Left Atrial Appendage System for Embolic PROTECTion in Patients with Atrial Fibrillation) trial. Am Heart J. 2006;151:956–961. - PubMed
    1. Singh G.D., Rogers J.H., Saw J. Watchman FLX: early "real world" experience in search for the perfect closure. JACC Cardiovasc Interv. 2020;13:2742–2744. - PubMed
    1. Grygier M., Markiewicz A., Araszkiewicz A., et al. Watchman FLX: the initial Polish experience with a new device for left atrial appendage occlusion. Kardiol Pol. 2020;78:240–242. - PubMed

Publication types

LinkOut - more resources